Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled “Systemic Lupus Erythematosus—Developing Medical Products for Treatment.” This guidance provides recommendations for industry on developing human drugs, therapeutic biological products, and medical devices for the treatment of systemic lupus erythematosus (SLE). This guidance finalizes the draft guidance entitled “Systemic Lupus Erythematosus—Developing Drugs for Treatment” (the draft guidance). Elsewhere in this issue of the Federal Register, FDA is announcing the availability of the guidance entitled “Lupus Nephritis Caused by Systemic Lupus Erythematosus—Developing Medical Products for Treatment,” which finalizes the parts of the draft guidance regarding lupus nephritis.
Submit either electronic or written comments on agency guidances at any time.
Submit written requests for single copies of this guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002; the Office of Communication, Outreach and Development (HFM-40), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448; or the Division of Small Manufacturers, International, and Consumer Assistance (HFZ-220), Center for Devices and Radiological Health, Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850. The guidance may also be obtained by mail by calling CBER at 1-800-835-4709 or 301-827-1800. Send one self-addressed adhesive label to assist the offices in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document.Start Printed Page 35494
Submit electronic comments on the guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Jeffrey Siegel, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, rm. 3154, Silver Spring, MD 20993-0002, 301-796-2280; or
Stephen Ripley, Center for Biologics Evaluation and Research (HFM-17), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852, 301-827-6210; or
Sahar M. Dawisha, Office of In Vitro Diagnostic Devices, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 2098 Gaither Rd., rm. 374, Rockville, MD 20850, 240-276-0717.End Further Info End Preamble Start Supplemental Information
FDA is announcing the availability of a guidance for industry entitled “Systemic Lupus Erythematosus—Developing Medical Products for Treatment.” This guidance is intended to assist sponsors in the clinical development of medical products for the treatment of SLE. The guidance addresses the overall development program and clinical trial designs as well as specific information on claims, study design, study duration, efficacy endpoints, and response criteria.
In the Federal Register of March 29, 2005 (70 FR 15868), FDA announced the availability of a draft guidance entitled “Systemic Lupus Erythematosus—Developing Drugs for Treatment.” FDA received a number of comments on the draft guidance, which were considered and incorporated, as appropriate, when finalizing the guidance. The recommendations regarding medical product development for lupus nephritis were removed from this guidance and placed into a separate guidance, the availability of which is announced elsewhere in this issue of the Federal Register. Additional organ-specific guidances will be developed in the future. Other changes that were made include the addition of more specific examples of trial design and study endpoints, updating the science, and minor editorial changes to clarify specific issues. In addition, input was obtained from the Center for Biologics Evaluation and Research and the Center for Devices and Radiological Health.
This guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents the agency's current thinking on developing medical products for the treatment of SLE. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.
II. The Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The collections of information in 21 CFR part 312 have been approved under OMB Control No. 0910-0014; the collections of information in 21 CFR part 314 have been approved under OMB Control No. 0910-0001; the collections of information in 21 CFR part 601 have been approved under OMB Control No. 0910-0338; and the collections of information in 21 CFR part 812 have been approved under OMB Control No. 0910-0078.
Interested persons may submit to the Division of Dockets Management (see ADDRESSES) either electronic or written comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
IV. Electronic Access
Persons with access to the Internet may obtain the document at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm, or http://www.regulations.gov.Start Signature
Dated: June 11, 2010.
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-15080 Filed 6-21-10; 8:45 am]
BILLING CODE 4160-01-S